CR20120094A - Un antibiótico novedoso que comprende un anticuerpo mimético, métodos de preparación y usos del mismo - Google Patents

Un antibiótico novedoso que comprende un anticuerpo mimético, métodos de preparación y usos del mismo

Info

Publication number
CR20120094A
CR20120094A CR20120094A CR20120094A CR20120094A CR 20120094 A CR20120094 A CR 20120094A CR 20120094 A CR20120094 A CR 20120094A CR 20120094 A CR20120094 A CR 20120094A CR 20120094 A CR20120094 A CR 20120094A
Authority
CR
Costa Rica
Prior art keywords
same
preparation methods
new antibiotic
mimetic antibody
mimetic
Prior art date
Application number
CR20120094A
Other languages
English (en)
Inventor
Xiaoqing Qiu
Original Assignee
Protein Design Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Lab Ltd filed Critical Protein Design Lab Ltd
Publication of CR20120094A publication Critical patent/CR20120094A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1217—Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención pertenece al campo de la biología y la medicina, y especialmente se relaciona a un antibiótico novedoso que comprende un anticuerpo mimético, sus métodos de preparación y usos de los mismos.
CR20120094A 2009-09-02 2012-02-23 Un antibiótico novedoso que comprende un anticuerpo mimético, métodos de preparación y usos del mismo CR20120094A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2009100921284A CN101633699B (zh) 2009-09-02 2009-09-02 一种含抗体模拟物的新型抗生素及其制备方法与应用

Publications (1)

Publication Number Publication Date
CR20120094A true CR20120094A (es) 2012-06-05

Family

ID=41593050

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120094A CR20120094A (es) 2009-09-02 2012-02-23 Un antibiótico novedoso que comprende un anticuerpo mimético, métodos de preparación y usos del mismo

Country Status (15)

Country Link
EP (1) EP2474558B1 (es)
CN (1) CN101633699B (es)
AP (1) AP3302A (es)
AU (1) AU2010291640B2 (es)
CR (1) CR20120094A (es)
DK (1) DK2474558T3 (es)
EA (1) EA028912B1 (es)
ES (1) ES2538840T3 (es)
IL (1) IL218435A (es)
MY (1) MY161926A (es)
NZ (1) NZ598593A (es)
SG (1) SG178503A1 (es)
UA (1) UA102325C2 (es)
WO (1) WO2011026447A1 (es)
ZA (1) ZA201201386B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101633699B (zh) * 2009-09-02 2012-02-15 畿晋庆堂国际生物技术有限公司 一种含抗体模拟物的新型抗生素及其制备方法与应用
CN102101888B (zh) * 2009-12-17 2013-03-20 畿晋庆三联（北京）生物技术有限公司 一种新型抗eb病毒所致肿瘤多肽及其应用与制备方法
CN102747041B (zh) * 2011-04-21 2014-07-16 畿晋庆三联（北京）生物技术有限公司 抗蓝藻重组抗体多肽及其基因与制备方法
CN103131724B (zh) * 2011-11-25 2015-02-25 畿晋庆三联（北京）生物技术有限公司 一种高效表达工程菌重组蛋白的方法及应用
DK2789632T3 (en) * 2011-12-08 2018-08-06 Protein Design Lab Ltd HOW TO UNKNOWN METHOD FOR PRODUCING ANTIBIOTICS AND PLATFORM SYSTEM BASED ON THESE
CN114369158B (zh) * 2021-09-28 2024-04-19 北京亦科信息菌素研究院有限公司 一种抗新冠病毒的信息菌素及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1330758C (zh) * 2005-01-21 2007-08-08 四川大学 抗真菌多肽及其制备方法
CN100485038C (zh) * 2005-09-13 2009-05-06 四川大学华西医院 小型化抗耐药金黄色葡萄球菌多肽及其应用与制备方法
WO2007083175A1 (en) * 2006-01-17 2007-07-26 West China Hospital, Sichuan University Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith
CN101215568B (zh) * 2008-01-18 2010-06-23 畿晋庆三联（北京）生物技术有限公司 抗炭疽多肽及其应用与制备方法
CN101633699B (zh) * 2009-09-02 2012-02-15 畿晋庆堂国际生物技术有限公司 一种含抗体模拟物的新型抗生素及其制备方法与应用

Also Published As

Publication number Publication date
MY161926A (en) 2017-05-15
ES2538840T3 (es) 2015-06-24
IL218435A0 (en) 2012-04-30
AU2010291640B2 (en) 2013-02-07
AP2012006185A0 (en) 2012-04-30
EA028912B1 (ru) 2018-01-31
EP2474558A4 (en) 2013-03-27
DK2474558T3 (en) 2015-06-15
ZA201201386B (en) 2013-08-28
AU2010291640A1 (en) 2012-03-22
CN101633699B (zh) 2012-02-15
CN101633699A (zh) 2010-01-27
NZ598593A (en) 2013-07-26
AP3302A (en) 2015-06-30
UA102325C2 (uk) 2013-06-25
EP2474558A1 (en) 2012-07-11
WO2011026447A1 (zh) 2011-03-10
EP2474558B1 (en) 2015-04-15
EA201200417A1 (ru) 2012-07-30
IL218435A (en) 2016-04-21
SG178503A1 (en) 2012-03-29
HK1168113A1 (en) 2012-12-21

Similar Documents

Publication Publication Date Title
MX338078B (es) Cristales de anticuerpos anti-esclerostina y formulaciones de los mismos.
MX353706B (es) Anticuerpos contra csf-1r humano y usos de los mismos.
CU24533B1 (es) Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
ECSP11011430A (es) Anticuerpos anti-egfl7 humanizados y métodos de uso de los mismos
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
UY34779A (es) Anticuerpos anti-il-23 y composiciones farmacéuticas que los contienen
CL2017003356A1 (es) Moduladores cot y métodos de uso de los mismos
MX353827B (es) Formas de rifaximina y usos de la misma.
CR20120184A (es) Anticuerpos monoclonales frente a progastrina y su usos
MX2021008976A (es) Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.
MX2019002979A (es) Formulaciones de anticuerpos.
CR20110091A (es) Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos
CO6721041A2 (es) Anticuerpo anti-pcsk9 y métodos de uso
UY34876A (es) Anticuerpos anti-egfr y usos de los mismos
CO6551674A2 (es) Anticuerpos anti-her3 y usos de los mismo
CL2012000429A1 (es) Uso de cepas de bifidobacterium longum para la elaboracion de una completa composicion que sirve para reducir los sintomas de alergias.
MX382840B (es) Regiones de anticuerpo modificado y sus usos.
ECSP12011701A (es) Anticuerpos anti-cdcp1 humanizados
ECSP13012859A (es) Anticuerpos del cea
MX2014009755A (es) Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
CU20130044A7 (es) Proceso para la preparación de inhibidores de pan-cdk de fórmula (i), e intermediarios de la preparación
CR20120094A (es) Un antibiótico novedoso que comprende un anticuerpo mimético, métodos de preparación y usos del mismo
BR112018011526A2 (pt) compostos policíclicos como inibidores da tirosina quinase de bruton
ECSP12011653A (es) Derivados de n1-acil-5-fluoropirimidinona
BR112015008389A2 (pt) compostos úteis na síntese de compostos de benzamida